Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity
Authors Ma X, Wang H, Jin S, Wu Y, Liang XJ
Received 21 December 2011
Accepted for publication 24 January 2012
Published 7 March 2012 Volume 2012:7 Pages 1313—1328
DOI https://doi.org/10.2147/IJN.S29371
Review by Single-blind
Peer reviewer comments 4
Xiaowei Ma*, Huan Wang*, Shubin Jin, Yan Wu, Xing-Jie Liang
Laboratory of Nanomedicine and Nanosafety, Division of Nanomedicine and Nanobiology, National Center for Nanoscience and Technology, People’s Republic of China; and CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, Beijing, People’s Republic of China
*These authors contributed equally to this work
Background: There is an urgent need to develop drug-loaded biocompatible nanoscale packages with improved therapeutic efficacy for effective clinical treatment. To address this need, a novel poly (2-hydroxyethyl methacrylate)-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine [PHEMA-g-(PLA-DPPE)] copolymer was designed and synthesized to enable these nanoparticles to be pH responsive under pathological conditions.
Methods: The structural properties and thermal stability of the copolymer was measured and confirmed by Fourier transform infrare d spectroscopy, nuclear magnetic resonance, and thermogravimetric analysis. In order to evaluate its feasibility as a drug carrier, paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles were prepared using the emulsion-solvent evaporation method.
Results: The PHEMA-g-(PLA-DPPE) nanoparticles could be efficiently loaded with paclitaxel and controlled to release the drug gradually and effectively. In vitro release experiments demonstrated that drug release was faster at pH 5.0 than at pH 7.4. The anticancer activity of the PHEMA-g-(PLA-DPPE) nanoparticles was measured in breast cancer MCF-7 cells in vivo and in vitro. In comparison with the free drug, the paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles could induce more significant tumor regression.
Conclusion: This study indicates that PHEMA-g-(PLA-DPPE) nanoparticles are promising carriers for hydrophobic drugs. This system can passively target cancer tissue and release drugs in a controllable manner, as determined by the pH value of the area in which the drug accumulates.
Keywords: poly (2-hydroxyethyl methacrylate), controlled release, biocompatibility, antitumor activity, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, nanoparticles
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Readers of this article also read:
Monitoring cancer stem cells: insights into clinical oncology
Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL
OncoTargets and Therapy 2016, 9:731-740
Published Date: 11 February 2016
A critical appraisal of the clinical utility of proton therapy in oncology
Wang D
Medical Devices: Evidence and Research 2015, 8:439-446
Published Date: 28 October 2015
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M
Drug Design, Development and Therapy 2015, 9:5215-5223
Published Date: 11 September 2015
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda MN, Niu J
Drug Design, Development and Therapy 2015, 9:3767-3777
Published Date: 24 July 2015
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Rocchi A, Chabot I, Glennie J
ClinicoEconomics and Outcomes Research 2015, 7:287-298
Published Date: 3 June 2015
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M
OncoTargets and Therapy 2015, 8:1149-1156
Published Date: 22 May 2015
Brachytherapy in the treatment of cervical cancer: a review
Banerjee R, Kamrava M
International Journal of Women's Health 2014, 6:555-564
Published Date: 28 May 2014
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Brueseke TJ, Tewari KS
Clinical Pharmacology: Advances and Applications 2013, 5:13-19
Published Date: 23 May 2013
Palliative nursing care for children and adolescents with cancer
Foster TL, Bell CJ, McDonald CF, Harris JS, Gilmer MJ
Nursing: Research and Reviews 2012, 2:17-25
Published Date: 15 June 2012
Multidisciplinary care in pediatric oncology
Cantrell MA, Ruble K
Journal of Multidisciplinary Healthcare 2011, 4:171-181
Published Date: 30 May 2011
